

EDITORIAL

CARLOS L. ALVIAR, MD

Assistant Professor, Division of Cardiovascular Medicine, University of Florida College of Medicine, Gainesville

GUSTAVO A. HERESI, MD

Medical Director, Pulmonary Thromboendarterectomy Program, Departments of Pulmonary Medicine and Critical Care Medicine, Respiratory Institute, Cleveland Clinic; Assistant Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH

Thrombolysis in submassive pulmonary embolism: Finding the balance

IN THIS ISSUE of the *Journal*, Ataya et al¹ provide a comprehensive review of thrombolysis in submassive pulmonary embolism, a subject of much debate. In *massive* pulmonary embolism, thrombolytic therapy is usually indicated²; in *submassive* pulmonary embolism, the decision is not so clear. Which patients with submassive embolism would benefit from thrombolysis, and which patients require only anticoagulant therapy? The answer lies in finding the balance between the potential benefit of thrombolytic therapy—preventing death or hemodynamic collapse—and the numerically low but potentially catastrophic risk of intracranial bleeding.

See related article, page 923

In general, submassive pulmonary embolism refers to an acute pulmonary embolus serious enough to cause evidence of right ventricular dysfunction or necrosis but not hemodynamic instability (ie, with systolic blood pressure > 90 mm Hg) on presentation.³ It accounts for about 25% of cases of pulmonary embolism,^{4,5} and perhaps 0.5 to 1% of patients admitted to intensive care units across the country.⁶ The 30-day mortality rate can be as high as 30%, making it a condition that requires prompt identification and appropriate management.

But clinical trials have failed to demonstrate a substantial improvement in mortality rates with thrombolytic therapy in patients with submassive pulmonary embolism, and have shown improvement only in other clinical end points.⁷ Part of the problem is that this

doi:10.3949/ccjm.83a.16099

TABLE 1

Predictors of death within 30 days in acute pulmonary embolism

Test	Cut-off value	Negative predictive value, %	Positive predictive value, %
Echocardiography	Various for right ventricular dysfunction	98	8
Computed tomographic pulmonary angiography	RV:LV diameter ratio \geq 0.9	93	8
B-type natriuretic peptide (BNP)	75–100 pg/mL	98	14
NT-pro-BNP	600 pg/mL	99	7
Troponin T	14 pg/mL	98	9

NT-pro-BNP = N-terminal pro-BNP

is a heterogeneous condition, posing a challenge for the optimal design and interpretation of studies.

WHO IS AT RISK OF DEATH OR DETERIORATION?

If clinicians could ascertain in each patient whether the risk-benefit ratio is favorable for thrombolytic therapy, it would be easier to provide optimal care. This is not a straightforward task, and it requires integration of clinical judgment, high index of suspicion for deterioration, and clinical tools.

One of the challenges is that it is difficult to identify normotensive patients at the high-

est risk of poor outcomes. Several factors are associated with a higher risk of death within 30 days (Table 1). While each of these has a negative predictive value of about 95% or even higher (meaning that it is very good at predicting who will *not* die), they all have very low positive predictive values (meaning that none of them, by itself, is very good at predicting who *will* die).

For this reason, a multimodal approach to risk stratification has emerged. For example, Jiménez et al⁸ showed that normotensive patients with acute pulmonary embolism and a combination of abnormal Simplified Pulmonary Embolism Severity Index, elevated B-type natriuretic peptide level, elevated troponin level, and lower-extremity deep vein thrombosis had a 26% rate of complications (death, hemodynamic collapse, or recurrent pulmonary embolism) within 30 days.

Bova et al⁹ showed that the combination of borderline low systolic blood pressure (90–100 mm Hg), tachycardia (heart rate \geq 110 beats per minute), elevated troponin, and right ventricular dysfunction by echocardiography or computed tomography allowed for the separation of three groups with significantly different rates of poor outcomes.

■ WHO IS AT RISK OF BLEEDING?

Estimation of the risk of bleeding is currently less sophisticated, and we need a bleeding score to use in the setting of acute pulmonary embolism. A few studies have shed some light on this issue beyond the known absolute and relative contraindications to thrombolysis.

Ataya et al¹ note a meta-analysis¹⁰ showing that systemic thrombolytic therapy was not associated with an increased risk of major bleeding in patients age 65 or younger. Similarly, a large observational study showed a strong association between the risk of intracerebral hemorrhage and increasing age¹¹ and also identified comorbidities such as kidney disease as risk factors. While the frequently cited Pulmonary Embolism Thrombolysis trial¹² showed a significantly higher risk of stroke with tenecteplase, careful review of its data reveals that all 10 of the 506 patients in the tenecteplase group who sustained a hemorrhagic stroke were age 65 or older.¹²

■ A TEAM APPROACH

Thus, in patients with acute pulmonary embolism, clinicians face the difficult task of assessing the patient's risk of death and clinical worsening and balancing that risk against the risk of bleeding, to identify those who may benefit from early reperfusion therapies, including systemic thrombolysis, catheter-directed thrombolysis, mechanical treatment, and surgical embolectomy.

Given the absence of high-quality evidence to guide these decisions, several institutions have developed multidisciplinary pulmonary embolism response teams to provide rapid evaluation and risk stratification and to recommend and implement advanced therapies, as appropriate. This is a novel concept that is still evolving but holds promise, as it integrates the experience and expertise of physicians in multiple specialties, such as pulmonary and critical care medicine, vascular medicine, interventional radiology, interventional cardiology, emergency medicine, and cardiothoracic surgery, who can then fill the currently existing knowledge gaps for clinical care and, possibly, research.¹³

Early published experience has documented the feasibility of this multidisciplinary approach.¹⁴ The first 95 patients treated at Cleveland Clinic had a 30-day mortality rate of 3.2%, which was lower than the expected 9% rate predicted by the Pulmonary Embolism Severity Index score (unpublished observation).

Figure 1 shows the algorithm currently used by Cleveland Clinic's pulmonary embolism response team, with the caveat that no algorithm can fully capture the extent of the complexities and discussions that each case triggers within the team.

■ TOWARD BETTER UNDERSTANDING

As Ataya et al point out,¹ the current state of the evidence does not allow a clear, simplistic, one-size-fits-all approach. A question that arises from this controversial topic is whether we should look for markers of right ventricular dysfunction in every patient admitted with a diagnosis of pulmonary embolism, or only in those with a significant anatomic burden of clot on imaging. Would testing everyone be an appropriate way to identify patients at risk

Which patients would benefit from thrombolysis, and which need only anticoagulation?




FIGURE 1. Cleveland Clinic pulmonary embolism response team algorithm.

of further deterioration early and therefore prevent adverse outcomes in a timely manner? Or would it not be cost-effective and translate into ordering more diagnostic testing, as well as an increase in downstream workup with higher healthcare costs?

Once we better understand this condition and the factors that predict a higher risk

of deterioration, we should be able to design prospective studies that can help elucidate the most appropriate diagnostic and therapeutic approach for such challenging cases. In the meantime, it is important to appraise the evidence in a critical way, as Ataya et al have done in their review. ■

REFERENCES

1. Ataya A, Cope J, Shahmohammadi A, Alnuaimat H. The role of thrombolytic therapy in patients with submassive pulmonary embolism. *Cleve Clin J Med* 2016; 83:923–932.
2. Kucher N, Goldhaber SZ. Management of massive pulmonary embolism. *Circulation* 2005; 112:e28–e32.
3. Busse LW, Vourlekis JS. Submassive pulmonary embolism. *Crit Care*

SUBMASSIVE PULMONARY EMBOLISM

- Clin 2014; 30:447–473.
4. **Tapson VF.** Acute pulmonary embolism. *N Engl J Med* 2008; 358:1037–1052.
 5. **Kucher N, Rossi E, De Rosa M, Goldhaber SZ.** Massive pulmonary embolism. *Circulation* 2006; 113:577–582.
 6. **Bahloul M, Chari A, Kallel H, et al.** Pulmonary embolism in intensive care unit: predictive factors, clinical manifestations and outcome. *Ann Thorac Med* 2010; 5:97–103.
 7. **Piazza G, Goldhaber SZ.** Fibrinolysis for acute pulmonary embolism. *Vasc Med* 2010; 15:419–428.
 8. **Jiménez D, Kopecna D, Tapson V, et al.** Derivation and validation of multimarker prognostication for normotensive patients with acute symptomatic pulmonary embolism. *Am J Respir Crit Care Med* 2014; 189:718–726.
 9. **Bova C, Sanchez O, Prandoni P, et al.** Identification of intermediate-risk patients with acute symptomatic pulmonary embolism. *Eur Respir J* 2014; 44:694–703.
 10. **Chatterjee S, Chakraborty A, Weinberg I, et al.** Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis. *JAMA* 2014; 311:2414–2421.
 11. **Stein PD, Matta F, Steinberger DS, Keyes DC.** Intracerebral hemorrhage with thrombolytic therapy for acute pulmonary embolism. *Am J Med* 2012; 125:50–56.
 12. **Meyer G, Vicaut E, Danays T, et al.** Fibrinolysis for patients with intermediate-risk pulmonary embolism. *N Engl J Med* 2014; 370:1402–1411.
 13. **Dudzinski DM, Piazza G.** Multidisciplinary pulmonary embolism response teams. *Circulation* 2016; 133:98–103.
 14. **Kabrhel C, Rosovsky R, Channick R, et al.** A multidisciplinary pulmonary embolism response team: initial 30-month experience with a novel approach to delivery of care to patients with submassive and massive pulmonary embolism. *Chest* 2016; 150:384–393.
- ADDRESS: Gustavo A. Heresi, MD, Respiratory Institute, A90, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; heresig@ccf.org



R.J. Fasenmyer Center for Clinical Immunology

Biologic Therapies VII Summit: Precision Medicine in the Biologic Era

April 6 – 8, 2017

InterContinental Hotel and Bank of America Conference Center | Cleveland, OH



Biologic Therapies VII Summit is an advanced course on cutting-edge translational immunology and the latest data on biologic therapeutics. This year's Summit will focus on precision medicine in the biologic era and kicks off with a fundamental immunologic plenary session, reviewing recent basic laboratory breakthroughs in terms of their potential clinical implications.

Why attend?

- Network with world leaders in immune-based therapies
- Join experts in discussions of recent and future targets
- Learn from diverse perspectives of multiple disciplines including rheumatology, dermatology, pulmonology and oncology
- Expand and enhance decision-making skills for appropriate use of biologic therapies in highly complex clinical situations

For more information, visit ccfcm.org/2017BioSummit

These activities have been approved for AMA PRA Category 1 Credit™.

KEYNOTE ADDRESS

R.J. Fasenmyer Annual Lectureship



Cytokine Profiles in Health and Disease – What Can They Inform Us?
Iain McInnes, MD, PhD
University of Glasgow, Scotland

Pre-Symposium

April 5, 2017

Primary Vasculitides: Best Practices and Future Advances

Attend for an update on the current standard of care and management of patients with primary vasculitides. Advances and future development in the treatment of primary vasculitides will be shared by the experts in this field.